www.magazine-industry-usa.com
31
'18
Written on Modified on
MEDIAWORLD
The world’s most advanced total artificial heart project
CARMAT announces the certification of its new automated manufacturing site for the production of up to 800 units a year at full capacity
The newly available space will allow the production of up to 800 units per year at full capacity to meet the demands of industrial-pace manufacturing as well as the enrollment ramp up in the ongoing PIVOTAL study. Furthermore, this facility will enable the use of new tools, such as robots, to assemble hybrid membranes on the device and a fully-automated software station to set up the prosthesis parameters. This project has been conducted by a dedicated team with the aim to implement best industrial practices in regards to the organization, processes, and IT systems for maximum efficiency and quality.
Stéphane Piat, Chief Executive Officer of CARMAT, commented: “We are delighted to announce the certification of our new manufacturing site based in Bois-d’Arcy, near Paris, which is a true accomplishment as we have achieved it in less than a year from the start of the building construction. CARMAT will now be able to manufacture products in both Vélizy and Bois-d’Arcy. In line with our strategy, the new automated site will enable CARMAT to become an industrial company with the ability to manufacture up to 800 units a year at full capacity in order to support the demand. Thanks to new processes, we will increase production throughput and more importantly, reinforce the quality of our prostheses to better serve patients across the world.”
A credible response to end-stage heart failure: CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.
The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.
Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming the necessary clinical trials are successful, potentially benefit the lives of thousands of patients a year with no risk of rejection and with a good quality of life.
www.carmatsa.com
